ArticleFrontiers in cardiovascular medicine2025
Global trends and stratified analysis of aortic aneurysm mortality: insights from the GBD 2021 study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Global, regional, and temporal trends in aortic aneurysm burden, 1990-2021: insights from the Global Burden of Disease study.Journal of thoracic disease · 2026Article
- The global burden of aortic aneurysm attributable to smoking from 1990 to 2021: Current trends and projections for 2036.Tobacco induced diseases · 2026Article
- Aortic dissection mortality in the United States, 1968-2023: Trends, disparities, and deep learning forecasts.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aortic aneurysm (AA) is a serious cardiovascular disease with a high mortality rate. The aim of this study was to provide an up-to-date assessment of global AA mortality rates from 1990 to 2021, stratified by age, sex, and sociodemographic indices (SDI). Method: This study utilized data from the Global Burden of Disease (GBD) 2021 Result: In 2021, the global number of deaths due to AA increased to 153,927.20 (95% UI: 138,413.36-165,738.65), while ASDR decreased to 1.86 per 100,000 (95% UI: 1.67-2.00). The estimated annual percentage change in ASDR was -0.81 (95% CI: -0.95 to -0.66), and the average annual percentage change was -0.99 (95% CI: -1.07 to -0.90). Significant regional differences were observed, with high SDI regions experiencing a notable decrease in mortality rates, while low and low-middle SDI regions saw a substantial increase in deaths and an upward trend in mortality rates. The annual percentage change in mortality rates for those aged 55-59 years and older was positive, identifying this age group as a significant risk factor for increased AA-related mortality. At the national level, the three countries with the highest ASDR were Armenia, Montenegro, and Nauru, while the three countries with the lowest ASDR were Saudi Arabia, Tajikistan, and Afghanistan. Predictive analyses suggest that although the number of AA-related deaths is expected to continue rising, mortality rates are projected to decline. Conclusion: While the global number of deaths from AA is anticipated to keep increasing, the ASDR is generally declining due to advances in medical care and improvements in early intervention. However, there are significant differences between countries and SDI regions. In low and low-middle SDI regions, the ASDR continues to rise, whereas in high and high-middle SDI regions, the ASDR is steadily decreasing but still remains higher than in lower SDI regions. Therefore, early screening and effective management of high-risk groups are crucial on a global scale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.